The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis

Bibliography

• Burger D, Dayer JM, Palmer G, et al. Is IL-1 a good therapeutic target in the treatment of arthritis? Best Pract Res Clin Rheumatol 2006;20:879-96
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;87:2095-147
   PubMed Web of Science ®Google Scholar
• Balavoine JF, de Rochemonteix B, Williamson K, et al. Prostaglandin E2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin 1 and inhibitor(s). J Clin Invest 1986;78:1120-4
   PubMed Web of Science ®Google Scholar
• Hannum CH, Wilcox CJ, Arend WP, et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 1990;343:336-40
   PubMed Web of Science ®Google Scholar
• Eisenberg SP, Evans RJ, Arend WP, et al. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 1990;343:341-6
   PubMed Web of Science ®Google Scholar
• Arend WP, Malyak M, Guthridge CJ, et al. Interleukin-1 receptor antagonist: role in biology. Ann Rev Immunol 1998;16:27-55
   PubMed Web of Science ®Google Scholar
• Horai R, Saijo S, Tanioka H, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000;191:313-20
   PubMed Web of Science ®Google Scholar
• Nicklin MJ, Hughes DE, Barton JL, et al. Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J Exp Med 2000;191:303-12
   PubMed Web of Science ®Google Scholar
• Fisher CJ Jr, Dhainaut JF, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994;271:1836-43
   PubMed Web of Science ®Google Scholar
• Cohen S, Hurd E, Cush J, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:614-24
   PubMed Web of Science ®Google Scholar
• Pascual V, Allantaz F, Arce E, et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005;201:1479-86
   PubMed Web of Science ®Google Scholar
• Fitzgerald AA, Leclercq SA, Yan A, et al. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum 2005;52:1794-803
   PubMed Web of Science ®Google Scholar
• Shinkai K, McCalmont TH, Leslie KS. Cryopyrin-associated periodic syndromes and autoinflammation. Clin Exp Dermatol 2008;33:1-9
   PubMed Web of Science ®Google Scholar
• de Koning HD, Bodar EJ, van der Meer JW, et al. Schnitzler Syndrome Study Group. Schnitzler syndrome: beyond the case reports. Review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum 2007;37:137-48
   PubMed Web of Science ®Google Scholar
• Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007;356:1517-26
   PubMed Web of Science ®Google Scholar
• So A, De Smedt T, Revaz S, et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007;9:R28
   PubMed Web of Science ®Google Scholar
• McGonagle D, Tan AL, Shankaranarayana S, et al. Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. Ann Rheum Dis 2007;66:1683-84
   PubMed Web of Science ®Google Scholar
• Wolfe F, Zwillich SH. The long-term outcomes of rheumatoid arthritis: a 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis. Arthritis Rheum 1998;41:1072-82
   PubMed Web of Science ®Google Scholar
• Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94
   PubMed Web of Science ®Google Scholar
• O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004;350:2591-602
   PubMed Web of Science ®Google Scholar
• Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93
   PubMed Web of Science ®Google Scholar
• Lipsky PE, van der Heijde DM, St Clair EW, et al.; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45
   PubMed Web of Science ®Google Scholar
• Cohen SB, Emery P, Greenwald MW, et al. REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806
   PubMed Web of Science ®Google Scholar
• Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006;144:865-76
   PubMed Web of Science ®Google Scholar
• Dayer JM, Bresnihan B. Targeting interleukin-1 in the treatment of rheumatoid arthritis. Arthritis Rheum 2002;46:574-8
   PubMed Web of Science ®Google Scholar
• Lebsack ME, Paul CC, Bloedow DC, et al. Subcutaneous IL-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 1991;34(Suppl):S45
   Google Scholar
• Campion GV, Lebsack ME, Lookabaugh J, et al. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group. Arthritis Rheum 1996;39:1092-101
   PubMed Web of Science ®Google Scholar
• Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-204
   PubMed Web of Science ®Google Scholar
• Jiang Y, Genant HK, Watt I, et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000;43:1001-9
   PubMed Web of Science ®Google Scholar
• Burls A, Jobanputra P. The trials of anakinra. Lancet 2004;364:827-8
   PubMed Web of Science ®Google Scholar
• Amgen. STN 103950, anakinra for use in the treatment of rheumatoid arthritis. Clinical Review 2001. Available at www.fda.gov/OHRMS/DOCKETS/AC/01/briefing/3779b1_02_Amgen-cber.pdf [Last accessed 21 January 2008]
   Google Scholar
• Cohen SB, Moreland LW, Cush JJ, et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 2004;63:1062-8
   PubMed Web of Science ®Google Scholar
• Fleischmann RM, Schechtman J, Bennett R, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum 2003;48:927-34
   PubMed Web of Science ®Google Scholar
• Fleischmann RM, Tesser J, Schiff MH, et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:1006-12
   PubMed Web of Science ®Google Scholar
• Schiff MH, Bulpitt K, Weaver AA, et al. Safety of combination therapy with anakinra and etanercept in patients with rheumatoid arthritis. Arthritis Rheum 2001;44(Suppl 9):S79
   Google Scholar
• Genovese MC, Cohen S, Moreland L, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004;50:1412-9
   PubMed Web of Science ®Google Scholar
• Nixon R, Bansback N, Brennan A. The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. Rheumatology (Oxford) 2007;46:1140-7
   PubMed Web of Science ®Google Scholar
• Gartlehner G, Hansen RA, Jonas BL, et al. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2006;33:2398-408
   PubMed Web of Science ®Google Scholar
• Clark W, Jobanputra P, Barton P, et al. The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis. Health Technol Assess 2004;8:iii-iv, ix-x, 1-105
   PubMed Web of Science ®Google Scholar
• Efthimiou P, Paik PK, Bielory L. Diagnosis and management of adult onset Still's disease. Ann Rheum Dis 2006;65:564-72
   PubMed Web of Science ®Google Scholar
• Bannatyne GA, Wohlmann AS. Rheumatoid arthritis: its clinical history, etiology and pathology. Lancet 1896;1:1120-5
   Google Scholar
• Bywaters EG. Still's disease in the adult. Ann Rheum Dis 1971;30:121-33
   PubMed Web of Science ®Google Scholar
• Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007;369:767-78
   PubMed Web of Science ®Google Scholar
• Efthimiou P, Kontzias A, Ward CM, et al. Adult-onset Still's disease: can recent advances in our understanding of its pathogenesis lead to targeted therapy? Nat Clin Pract Rheumatol 2007;3:328-35
   PubMedGoogle Scholar
• Hashkes PJ, Laxer RM. Medical treatment of juvenile idiopathic arthritis. JAMA 2005;294:1671-84
   PubMed Web of Science ®Google Scholar
• Kimura Y, Pinho P, Walco G, et al. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol 2005;32(5):935-42
   PubMed Web of Science ®Google Scholar
• Fautrel B, Sibilia J, Mariette X, et al. Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases. Ann Rheum Dis 2005;64:262-6
   PubMed Web of Science ®Google Scholar
• Yokota S, Miyamae T, Imagawa T, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2005;52:818-25
   PubMed Web of Science ®Google Scholar
• Iwamoto M, Nara H, Hirata D, et al. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease. Arthritis Rheum 2002;46:3388-9
   PubMed Web of Science ®Google Scholar
• Stambe C, Wicks IP. TNFalpha and response of treatment-resistant adult-onset Still's disease to thalidomide. Lancet 1998;352:544-5
   PubMed Web of Science ®Google Scholar
• Lehman TJ, Schechter SJ, Sundel RP, et al. Thalidomide for severe systemic onset juvenile rheumatoid arthritis: a multicenter study. J Pediatr 2004;145:856-7
   PubMed Web of Science ®Google Scholar
• Reiff A. The use of anakinra in juvenile arthritis. Curr Rheumatol Rep 2005;7:434-40
   PubMedGoogle Scholar
• Irigoyen PI, Olson J, Hom C, et al. Treatment of systemic onset juvenile idiopathic arthritis with anakinra. Pediatr Rheumatol Online J 2005. Available from: http://www.pedrheumonlinejournal.org/June%202006/June%2030%20issue/HTML/Anakinra%20final.htm
   Google Scholar
• Verbsky JW, White AJ. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 2004;31:2071-5
   PubMed Web of Science ®Google Scholar
• Hendrickson M. Efficacy of anakinra in refractory systemic arthritis. Arthritis Rheum 2004;50:S438
   Google Scholar
• Weiss J, Henrickson M, Walco G, et al. Combination therapy with anakinra and anti-TNF agents in refractory systemic JIA (SJIA). ACR 2005;134:S84
   Google Scholar
• Lurati A, Teruzzi B, Salmaso A, et al. Macrophage activation syndrome (MAS) during anti-IL1 receptor therapy (anakinra) in a patient affected by systemic idiopathic juvenile arthritis (soJIA): a report and review of the literature. Pediatr Rheumatol Online J 2007;3:79-85
   Google Scholar
• Zeft A, Schlesinger M, Bohnsack J. Anakinra in systemic juvenile idiopathic arthritis – The Intermountain West Experience. ACR 2006;1704:375
   Google Scholar
• Mirkinson LJ, Nagle D, Kadom N, et al. Anakinra therapy in a child with systemic-onset juvenile rheumatoid arthritis after human herpesvirus 6 encephalitis. J Clin Rheumatol 2006;12:83-6
   PubMed Web of Science ®Google Scholar
• Gattorno M, Brisca G, Ferlito F, et al. Different pattern of IL-1β secretion and response to anti IL-1 treatment in patients with systemic onset juvenile idiopathic arthritis (soJIA). ACR 2007;249:S144
   Google Scholar
• Pereda CA, Feito JG. Anakinra (AKR) proves clinical efficacy in two cases of refractory Still's disease. Ann Rheum Dis 2006;65(Suppl II):261
   PubMedGoogle Scholar
• Lequerré T, Quartier P, Rosellini D, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still's disease. Preliminary experience in France. Ann Rheum Dis 2007; [Epub ahead of print]
   PubMedGoogle Scholar
• Quartier P, Cimaz R, Pillet P, et al. Anakinra in systemic-onset juvenile idiopathic arthritis (ANAJIS trial): preliminary results. ACR 2007;CRC02:S35
   Google Scholar
• Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biologic agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 2007;66(Suppl 3):iii2-iii22
   PubMed Web of Science ®Google Scholar
• Rudinskaya A, Trock DH. Successful treatment of a patient with refractory adult-onset still disease with anakinra. J Clin Rheumatol 2003;9:330-2
   PubMed Web of Science ®Google Scholar
• Aelion J, Odhav S. Prompt response to treatment with anakinra in adult onset Still's disease. Ann Rheum Dis 2004;63(Suppl):281
   Google Scholar
• Haraoui B, Bourrelle D, Kaminska E. Anakinra in the treatment of adult onset Still's disease. Ann Rheum Dis 2004;63(Suppl):293-4
   Google Scholar
• Vasques Godinho FM, Parreira Santos MJ, Canas da Silva J. Refractory adult onset Still's disease successfully treated with anakinra. Ann Rheum Dis 2005;64:647-8
   PubMed Web of Science ®Google Scholar
• Aarntzen EH, van Riel PL, Barrera P. Refractory adult onset Still's disease and hypersensitivity to non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors: are biological agents the solution? Ann Rheum Dis 2005;64:1523-4
   PubMed Web of Science ®Google Scholar
• Kalliolias GD, Georgiou PE, Antonopoulos IA, et al. Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial. Ann Rheum Dis 2007;66:842-3
   PubMed Web of Science ®Google Scholar
• Nordstrom D, Aarnio M, Helve T, et al. Favorable response to anakinra in refractory adult-onset Still's disease. A clinical study is needed. ACR 2006;1623:294
   Google Scholar
• Naumann L, Feist E, Natusch A, et al. Interleukin-1 receptor antagonist anakinra proves long-lasting efficacy in the treatment of refractory adult-onset Still's disease. Ann Rheum Dis 2007;66(Suppl.II):434
   Google Scholar
• Quartuccio L, De Vita S. Interleukin 1 receptor antagonist therapy-induced thrombocytopenia in adult onset Still's disease. J Rheumatol 2007;34:892-893
   PubMed Web of Science ®Google Scholar
• Ruiz PJ, Masliah E, Doherty TA, et al. Cardiac death in a patient with adult-onset Still's disease treated with the interleukin 1 receptor inhibitor anakinra. Ann Rheum Dis 2007;66:422-3
   PubMedGoogle Scholar
• Kötter I, Wacker A, Koch S, et al. Anakinra in patients with treatment-resistant adult-onset still's disease: four case reports with serial cytokine measurements and a review of the literature. Semin Arthritis Rheum 2007;37:189-97
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Blocking IL-1 in systemic inflammation. J Exp Med 2005;201:1355-9
   PubMed Web of Science ®Google Scholar
• Hawkins PN, Lachmann HJ, Aganna E, et al. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004;50:607-12
   PubMed Web of Science ®Google Scholar
• Hoffman HM, Rosengren S, Boyle DL, et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004;364:1779-85
   PubMed Web of Science ®Google Scholar
• Caroli F, Pontillo A, D'Osualdo A, et al. Clinical and genetic characterization of Italian patients affected by CINCA syndrome. Rheumatology (Oxford) 2007;46:473-8
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Bowyer SL, Solinger AM. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Arthritis Rheum 2005;52:1283-6
   PubMed Web of Science ®Google Scholar
• Granel B, Serratrice J, Disdier P, et al. Dramatic improvement with anakinra in a case of chronic infantile neurological cutaneous and articular (CINCA) syndrome. Rheumatology (Oxford) 2005;44:689-90
   PubMed Web of Science ®Google Scholar
• Lequerré T, Vittecoq O, Saugier-Veber P, et al. A cryopyrin-associated periodic syndrome with joint destruction. Rheumatology (Oxford) 2007;46:709-14
   PubMed Web of Science ®Google Scholar
• Drenth JP, van der Meer JW. Hereditary periodic fever. N Engl J Med 2001;345:1748-57
   PubMed Web of Science ®Google Scholar
• Belkhir R, Moulonguet-Doleris L, Hachulla E, et al. Treatment of familial Mediterranean fever with anakinra. Ann Intern Med 2007;146:825-6
   PubMed Web of Science ®Google Scholar
• Dierselhuis MP, Frenkel J, Wulffraat NM, et al. Anakinra for flares of pyogenic arthritis in PAPA syndrome. Rheumatology (Oxford) 2005;44:406-8
   PubMed Web of Science ®Google Scholar
• Shoham NG, Centola M, Mansfield E, et al. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci USA 2003;100:13501-6
   PubMed Web of Science ®Google Scholar
• Martinon F, Pétrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440:237-41
   PubMed Web of Science ®Google Scholar
• Simon A, Bodar EJ, van der Hilst JC, et al. Beneficial response to interleukin 1 receptor antagonist in traps. Am J Med 2004;117:208-10
   PubMed Web of Science ®Google Scholar
• Bodar EJ, van der Hilst JC, Drenth JP, et al. Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. Neth J Med 2005;63:260-4
   PubMed Web of Science ®Google Scholar
• Rigante D, Ansuini V, Bertoni B, et al. Treatment with anakinra in the hyperimmunoglobulinemia D/periodic fever syndrome. Rheumatol Int 2006;27:97-100
   PubMed Web of Science ®Google Scholar
• Eiling E, Möller M, Kreiselmaier I, et al. Schnitzler syndrome: treatment failure to rituximab but response to anakinra. J Am Acad Dermatol 2007;57:361-4
   PubMed Web of Science ®Google Scholar
• Dinarello CA. The many worlds of reducing interleukin-1. Arthritis Rheum 2005;52:1960-7
   PubMed Web of Science ®Google Scholar
• Allantaz F, Chaussabel D, Stichweh D, et al. Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J Exp Med 2007;204:2131-44
   PubMed Web of Science ®Google Scholar
• Economides AN, Carpenter LR, Rudge JS, et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med 2003;9:47-52
   PubMed Web of Science ®Google Scholar
• Interleukin-1 Trap to treat autoinflammatory disease. Available at http://clinicaltrials.gov/ct2/show/NCT00094900?term=IL-1trap&rank=1 [Last accessed 21 January 2008]
   Google Scholar
• Pavelka K, Rasmussen MJ, Mikkelsen K, et al. Clinical effects of pralnacasan (PRAL), an orally-active interleukine-1 beta converting enzyme (ICE) inhibitor, in a 285 patient phase II trial in rheumatoid arthritis. Arthritis Rheum 2002;46:LB02
   Google Scholar